Trials Sponsors Conditions Drugs Pricing

Conditions

Hodgkin's Disease Pediatric

Keywords

PediatricHodgkin's Disease96-016

Outcome Measures

Primary Outcomes (1)

Determine the role of adjuvant low dose involved field radiotherapy in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy
Conclusion of the study

Study Arms (3)

1

EXPERIMENTAL

Drug: COPP/ABV

2

EXPERIMENTAL

Drug: COPP/ABV

3

EXPERIMENTAL

Drug: intensive chemo with concurrent growth factor

Interventions

COPP/ABVDrug

4 courses of COPP/ABV hybrid

Also known as: Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Adriamycin, Bleomycin, Vinblastine

COPP/ABVDrug

6 courses of COPP/ABV hybrid

Also known as: Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Adriamycin, Bleomycin, Vinblastine

Eligibility Criteria

AgeUp to 21 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

* Age less than 21 years at diagnosis * Previously untreated, pathologically confirmed diagnosis of Hodgkin's disease. * Informed patient/parental consent as required by individual institution and in accordance with the Dept of Health and Human Services * Approval of this protocol by the individual institutional Human Subjects Review Committee. * Indicate Hodgkin's disease clinical stage. * Indicate presence or absence of "B" symptoms. * For Stage I and II disease indicate the following: * presence or absence of bulk disease * number of involved nodal regions * presence or absence of hilar adenopathy

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Memorial Sloan Kettering Cancer Center
Otherlead
Children's Cancer Group
Othercollaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

MeSH Terms

Conditions

Hodgkin Disease

Interventions

CVPPABO protocolCyclophosphamideVincristineProcarbazinePrednisoneDoxorubicinBleomycinVinblastineCytarabineEtoposideGranulocyte Colony-Stimulating FactorFilgrastim

Condition Hierarchy (Ancestors)

Lymphoma

Study Officials

Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
PRINCIPAL INVESTIGATOR

Enrollment

21 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 26, 2007

First Posted

January 11, 2008

Study Start

March 1996

Date type not reported

This date has not been verified as actual or estimated.

A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

First Submitted

Study Completion

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

1

2

3

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

Study Completion

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

1

2

3

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations